Company · founded 2012
Metaclipse Therapeutics (United States)
Atlanta, United States · metaclipse.com
- Citations, last 5 years
- 36
- Works, last 5 years
- 8
- h-index
- 20
- Scientists listed
- 2
- Grants since 2016
- 12
Grants received
2025–2026 · contract · N43
SBIR CONCEPT AWARD FOR DEVELOPMENT OF THERAPEUTIC OR PREVENTATIVE TECHNOLOGIES FOR TREATMENT OR PREVENTION OF PEDIATRIC CANCERS AND/OR RARE CANCERS
Christopher Pack · Metaclipse Therapeutics (United States) · funded by National Institutes of Health
2024 · grant · Product Development Research
Personalized Immunotherapy for Recurrent, Resectable Head and Neck Cancer
Christopher Pack · Metaclipse Therapeutics (United States) · funded by Cancer Prevention and Research Institute of Texas
2022–2023 · research · R44
Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer
Christopher D Pack · Metaclipse Therapeutics (United States) · funded by National Institutes of Health
2021–2023 · research · R44
Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer
Christopher D Pack · Metaclipse Therapeutics (United States) · funded by National Institutes of Health
2021–2024 · research · R44
Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer
Christopher D Pack · Metaclipse Therapeutics (United States) · funded by National Institutes of Health
2021–2025 · research · R44
Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer
Christopher D Pack · Metaclipse Therapeutics (United States) · funded by National Institutes of Health
2019 · research · R44
IND enabling studies for a personalized immunotherapy for triple negative breast cancer
Kamal V. Kannan · Metaclipse Therapeutics (United States) · funded by National Institutes of Health
2019–2022 · contract · N44
Development of a SARS-CoV-2 vaccine for the elderly by engineering virus-like particles with SARS-CoV-2 antigen and membrane-anchored cytokines
Christopher Pack · Metaclipse Therapeutics (United States) · funded by National Institutes of Health
2019–2022 · contract · N44
Development of Membrane Anchored Cytokines as Novel Vaccine Adjuvants for the Elderly
Christopher Pack · Metaclipse Therapeutics (United States) · funded by National Institutes of Health
2017–2019 · research · R44
Membrane-based vaccine with checkpoint blockade for triple negative breast cancer
Kamal V. Kannan · Metaclipse Therapeutics (United States) · funded by National Institutes of Health
2017–2019 · research · R44
Membrane-based vaccine with checkpoint blockade for triple negative breast cancer
Kamal V. Kannan · Metaclipse Therapeutics (United States) · funded by National Institutes of Health
2017–2019 · contract · N43
Development of membrane anchored cytokines as novel vaccine adjuvants for the elderly
Christopher Pack · Metaclipse Therapeutics (United States) · funded by National Institutes of Health
